Quarterly Holdings Report
for
Fidelity® Series Growth Company Fund
August 31, 2022
XS7-NPRT3-1022
1.968013.108
Common Stocks - 97.1% | |||
Shares | Value ($) | ||
COMMUNICATION SERVICES - 8.8% | |||
Diversified Telecommunication Services - 0.0% | |||
IHS Holding Ltd. | 23,800 | 154,224 | |
Starry, Inc. | 1,218,562 | 2,604,676 | |
2,758,900 | |||
Entertainment - 0.8% | |||
Electronic Arts, Inc. | 5,454 | 691,949 | |
Netflix, Inc. (a) | 219,629 | 49,100,259 | |
Roblox Corp. (a)(b) | 179,000 | 7,000,690 | |
Roku, Inc. Class A (a) | 377,376 | 25,661,568 | |
The Walt Disney Co. (a) | 70,476 | 7,898,950 | |
90,353,416 | |||
Interactive Media & Services - 7.3% | |||
Alphabet, Inc.: | |||
Class A (a) | 4,603,980 | 498,242,716 | |
Class C (a) | 2,606,860 | 284,538,769 | |
IAC (a) | 13,600 | 874,072 | |
Meta Platforms, Inc. Class A (a) | 421,730 | 68,712,469 | |
Snap, Inc. Class A (a) | 426,581 | 4,641,201 | |
Taboola.com Ltd. (a) | 363,386 | 912,099 | |
Twitter, Inc. (a) | 122,881 | 4,761,639 | |
Vimeo, Inc. (a) | 1,445,820 | 8,559,254 | |
Zoominfo Technologies, Inc. (a) | 53,600 | 2,434,512 | |
873,676,731 | |||
Wireless Telecommunication Services - 0.7% | |||
T-Mobile U.S., Inc. (a) | 553,153 | 79,631,906 | |
TOTAL COMMUNICATION SERVICES | 1,046,420,953 | ||
CONSUMER DISCRETIONARY - 20.5% | |||
Automobiles - 3.0% | |||
Neutron Holdings, Inc. (a)(c)(d) | 438,358 | 12,055 | |
Rad Power Bikes, Inc. (a)(c)(d) | 249,183 | 1,542,443 | |
Rivian Automotive, Inc. (b) | 1,839,319 | 60,164,124 | |
Tesla, Inc. (a) | 1,057,755 | 291,527,856 | |
XPeng, Inc. ADR (a) | 283,700 | 5,254,124 | |
358,500,602 | |||
Hotels, Restaurants & Leisure - 1.9% | |||
Airbnb, Inc. Class A (a) | 151,000 | 17,081,120 | |
Booking Holdings, Inc. (a) | 29,672 | 55,659,034 | |
Chipotle Mexican Grill, Inc. (a) | 13,470 | 21,508,896 | |
Dutch Bros, Inc. (b) | 42,500 | 1,551,250 | |
Expedia, Inc. (a) | 85,600 | 8,786,840 | |
Hyatt Hotels Corp. Class A (a) | 8,383 | 751,284 | |
Marriott International, Inc. Class A | 379,050 | 58,275,147 | |
McDonald's Corp. | 5,925 | 1,494,759 | |
Penn Entertainment, Inc. (a) | 774,600 | 24,190,758 | |
Shake Shack, Inc. Class A (a) | 35,936 | 1,712,710 | |
Sonder Holdings, Inc. (a)(b) | 1,368,972 | 2,546,288 | |
Sonder Holdings, Inc.: | |||
rights (a)(d) | 14,240 | 14,240 | |
rights (a)(d) | 14,240 | 12,674 | |
rights (a)(d) | 14,239 | 11,391 | |
rights (a)(d) | 14,239 | 10,394 | |
rights (a)(d) | 14,238 | 9,397 | |
rights (a)(d) | 14,238 | 8,685 | |
Starbucks Corp. | 165,953 | 13,951,669 | |
Sweetgreen, Inc. Class A | 436,251 | 7,377,004 | |
Yum China Holdings, Inc. | 159,612 | 7,998,157 | |
222,951,697 | |||
Household Durables - 0.4% | |||
Lennar Corp. Class A | 466,369 | 36,120,279 | |
PulteGroup, Inc. | 30,900 | 1,256,394 | |
Purple Innovation, Inc. (a)(b) | 1,235,887 | 3,534,637 | |
Vizio Holding Corp. (a) | 50,700 | 543,504 | |
41,454,814 | |||
Internet & Direct Marketing Retail - 6.9% | |||
Alibaba Group Holding Ltd. sponsored ADR (a) | 49,900 | 4,760,959 | |
Amazon.com, Inc. (a) | 5,458,360 | 691,956,297 | |
Etsy, Inc. (a) | 32,581 | 3,440,879 | |
JD.com, Inc. sponsored ADR | 63,029 | 4,001,711 | |
Lyft, Inc. (a) | 530,568 | 7,815,267 | |
Pinduoduo, Inc. ADR (a) | 71,700 | 5,112,210 | |
Revolve Group, Inc. (a) | 465,100 | 10,925,199 | |
RumbleON, Inc. Class B (a) | 204,000 | 4,457,400 | |
Uber Technologies, Inc. (a) | 1,453,504 | 41,802,775 | |
Wayfair LLC Class A (a)(b) | 821,805 | 43,317,342 | |
Zomato Ltd. (a) | 6,700,000 | 4,787,021 | |
822,377,060 | |||
Leisure Products - 0.0% | |||
Peloton Interactive, Inc. Class A (a)(b) | 44,442 | 452,864 | |
Multiline Retail - 0.6% | |||
Dollar General Corp. | 111,840 | 26,553,053 | |
Dollar Tree, Inc. (a) | 94,194 | 12,780,242 | |
Ollie's Bargain Outlet Holdings, Inc. (a) | 445,182 | 24,623,016 | |
Target Corp. | 67,413 | 10,809,000 | |
74,765,311 | |||
Specialty Retail - 2.5% | |||
Carvana Co. Class A (a) | 28,224 | 931,110 | |
Fanatics, Inc. Class A (c)(d) | 153,984 | 11,254,691 | |
Five Below, Inc. (a) | 68,000 | 8,695,840 | |
Floor & Decor Holdings, Inc. Class A (a) | 99,200 | 8,070,912 | |
Lowe's Companies, Inc. | 408,823 | 79,368,897 | |
RH (a) | 39,529 | 10,115,866 | |
Ross Stores, Inc. | 123,400 | 10,645,718 | |
The Home Depot, Inc. | 310,477 | 89,547,776 | |
TJX Companies, Inc. | 1,324,372 | 82,574,594 | |
301,205,404 | |||
Textiles, Apparel & Luxury Goods - 5.2% | |||
Canada Goose Holdings, Inc. (a) | 344,371 | 6,203,844 | |
Crocs, Inc. (a) | 117,100 | 8,630,270 | |
Deckers Outdoor Corp. (a) | 153,170 | 49,254,877 | |
lululemon athletica, Inc. (a) | 1,369,758 | 410,872,610 | |
NIKE, Inc. Class B | 370,554 | 39,445,473 | |
On Holding AG | 1,346,900 | 26,924,531 | |
Skechers U.S.A., Inc. Class A (sub. vtg.) (a) | 1,625,179 | 61,431,766 | |
Tory Burch LLC (a)(c)(d)(e) | 248,840 | 9,543,014 | |
612,306,385 | |||
TOTAL CONSUMER DISCRETIONARY | 2,434,014,137 | ||
CONSUMER STAPLES - 4.8% | |||
Beverages - 1.9% | |||
Celsius Holdings, Inc. (a) | 25,900 | 2,680,391 | |
Constellation Brands, Inc. Class A (sub. vtg.) | 64,500 | 15,870,225 | |
Keurig Dr. Pepper, Inc. | 686,271 | 26,160,651 | |
Monster Beverage Corp. (a) | 647,235 | 57,493,885 | |
PepsiCo, Inc. | 212,864 | 36,670,081 | |
The Coca-Cola Co. | 1,351,007 | 83,370,642 | |
222,245,875 | |||
Food & Staples Retailing - 1.0% | |||
Blink Health LLC Series A1 (a)(c)(d) | 8,589 | 325,867 | |
Costco Wholesale Corp. | 134,244 | 70,088,792 | |
Grocery Outlet Holding Corp. (a) | 129,400 | 5,191,528 | |
Kroger Co. | 227,540 | 10,908,268 | |
Ocado Group PLC (a) | 34,920 | 294,513 | |
Performance Food Group Co. (a) | 392,268 | 19,605,555 | |
Sysco Corp. | 174,400 | 14,339,168 | |
120,753,691 | |||
Food Products - 0.6% | |||
Archer Daniels Midland Co. | 118,200 | 10,388,598 | |
Bunge Ltd. | 251,154 | 24,906,942 | |
Darling Ingredients, Inc. (a) | 192,869 | 14,669,616 | |
Kellogg Co. | 99,100 | 7,208,534 | |
Mondelez International, Inc. | 80,717 | 4,993,154 | |
Oatly Group AB ADR (a)(b) | 417,900 | 1,349,817 | |
The Hershey Co. | 53,100 | 11,929,977 | |
The Real Good Food Co. LLC: | |||
Class B (d) | 131,479 | 1 | |
Class B unit (f) | 131,479 | 937,445 | |
The Real Good Food Co., Inc. | 11,600 | 82,708 | |
76,466,792 | |||
Household Products - 0.5% | |||
Church & Dwight Co., Inc. | 79,521 | 6,656,703 | |
Colgate-Palmolive Co. | 132,191 | 10,338,658 | |
Procter & Gamble Co. | 274,878 | 37,916,671 | |
54,912,032 | |||
Personal Products - 0.3% | |||
Olaplex Holdings, Inc. (b) | 1,935,700 | 25,783,524 | |
The Beauty Health Co. (a) | 249,298 | 2,891,857 | |
The Beauty Health Co. (a)(c) | 553,828 | 6,424,405 | |
35,099,786 | |||
Tobacco - 0.5% | |||
JUUL Labs, Inc. Class A (a)(c)(d) | 13,297 | 102,387 | |
Philip Morris International, Inc. | 598,500 | 57,150,765 | |
57,253,152 | |||
TOTAL CONSUMER STAPLES | 566,731,328 | ||
ENERGY - 3.9% | |||
Energy Equipment & Services - 0.5% | |||
Baker Hughes Co. Class A | 462,700 | 11,687,802 | |
Halliburton Co. | 925,400 | 27,882,302 | |
Schlumberger Ltd. | 618,600 | 23,599,590 | |
63,169,694 | |||
Oil, Gas & Consumable Fuels - 3.4% | |||
Cameco Corp. (b) | 580,700 | 16,927,405 | |
ConocoPhillips Co. | 82,200 | 8,996,790 | |
Devon Energy Corp. | 283,600 | 20,027,832 | |
EOG Resources, Inc. | 358,900 | 43,534,570 | |
EQT Corp. | 75,600 | 3,613,680 | |
Exxon Mobil Corp. | 48,100 | 4,597,879 | |
Hess Corp. | 1,081,906 | 130,672,607 | |
Occidental Petroleum Corp. | 434,800 | 30,870,800 | |
Phillips 66 Co. | 83,500 | 7,469,910 | |
Pioneer Natural Resources Co. | 133,900 | 33,906,158 | |
Range Resources Corp. | 1,194,400 | 39,247,984 | |
Reliance Industries Ltd. | 1,195,359 | 39,141,151 | |
Valero Energy Corp. | 183,500 | 21,491,520 | |
400,498,286 | |||
TOTAL ENERGY | 463,667,980 | ||
FINANCIALS - 1.8% | |||
Banks - 0.8% | |||
Bank of America Corp. | 874,817 | 29,402,599 | |
First Republic Bank | 106,400 | 16,154,712 | |
HDFC Bank Ltd. sponsored ADR | 417,422 | 25,483,613 | |
JPMorgan Chase & Co. | 112,123 | 12,751,749 | |
Wells Fargo & Co. | 57,900 | 2,530,809 | |
86,323,482 | |||
Capital Markets - 0.7% | |||
BlackRock, Inc. Class A | 43,097 | 28,719,410 | |
Charles Schwab Corp. | 806,951 | 57,253,173 | |
85,972,583 | |||
Consumer Finance - 0.0% | |||
Discover Financial Services | 22,082 | 2,219,020 | |
Diversified Financial Services - 0.3% | |||
Adimab LLC (a)(c)(d)(e) | 762,787 | 33,079,860 | |
Ant International Co. Ltd. Class C (a)(c)(d) | 617,086 | 1,104,584 | |
34,184,444 | |||
TOTAL FINANCIALS | 208,699,529 | ||
HEALTH CARE - 14.4% | |||
Biotechnology - 7.7% | |||
4D Pharma PLC (a)(b)(d) | 596,200 | 115,388 | |
AbbVie, Inc. | 127,549 | 17,150,239 | |
ACADIA Pharmaceuticals, Inc. (a) | 1,204,071 | 19,782,887 | |
Adagio Therapeutics, Inc. (b) | 1,686,417 | 7,690,062 | |
ADC Therapeutics SA (a) | 171,500 | 1,169,630 | |
Akouos, Inc. (a) | 89,500 | 299,825 | |
Akouos, Inc. (a)(f) | 113,263 | 379,431 | |
Alector, Inc. (a) | 326,260 | 3,376,791 | |
Allovir, Inc. (a)(b) | 471,210 | 3,538,787 | |
Alnylam Pharmaceuticals, Inc. (a) | 636,731 | 131,593,196 | |
Ambrx Biopharma, Inc. ADR (a) | 72,486 | 119,602 | |
Amgen, Inc. | 111,804 | 26,866,501 | |
Arcutis Biotherapeutics, Inc. (a) | 169,300 | 4,562,635 | |
Argenx SE ADR (a) | 213,460 | 80,660,130 | |
Arrowhead Pharmaceuticals, Inc. (a) | 40,359 | 1,602,656 | |
Ascendis Pharma A/S sponsored ADR (a) | 9,489 | 849,930 | |
aTyr Pharma, Inc. (a) | 228,431 | 781,234 | |
Avidity Biosciences, Inc. (a) | 327,400 | 6,423,588 | |
Axcella Health, Inc. (a) | 677,970 | 1,667,806 | |
Beam Therapeutics, Inc. (a)(b) | 110,100 | 6,011,460 | |
BeiGene Ltd. ADR (a) | 253,639 | 43,539,671 | |
Biogen, Inc. (a) | 1,642 | 320,814 | |
BioNTech SE ADR | 1,402 | 202,785 | |
BioXcel Therapeutics, Inc. (a)(b) | 308,998 | 4,227,093 | |
Century Therapeutics, Inc. (a) | 336,800 | 3,543,136 | |
Cerevel Therapeutics Holdings (a) | 1,622,816 | 47,223,946 | |
Cibus Corp. Series C (a)(c)(d)(e) | 2,017,507 | 4,983,242 | |
Codiak Biosciences, Inc. (a) | 309,262 | 664,913 | |
CRISPR Therapeutics AG (a)(b) | 204,500 | 13,310,905 | |
Cyclerion Therapeutics, Inc. (a) | 141,500 | 118,860 | |
Cyclerion Therapeutics, Inc. (a)(c) | 150,550 | 126,462 | |
Day One Biopharmaceuticals, Inc. (a) | 297,500 | 6,988,275 | |
Denali Therapeutics, Inc. (a) | 46,074 | 1,274,868 | |
Deverra Therapeutics, Inc. (a)(d) | 20,487 | 35,238 | |
EQRx, Inc. (a) | 1,724,649 | 8,433,534 | |
EQRx, Inc.: | |||
rights (a)(d) | 90,566 | 303,396 | |
rights (a)(d) | 38,814 | 103,245 | |
Erasca, Inc. (a) | 76,600 | 690,932 | |
Evelo Biosciences, Inc. (a)(b) | 1,263,014 | 2,766,001 | |
Foghorn Therapeutics, Inc. (a) | 310,983 | 3,091,171 | |
Gemini Therapeutics, Inc. (a)(b) | 16,800 | 26,040 | |
Generation Bio Co. (a)(b) | 647,360 | 3,314,483 | |
Icosavax, Inc. (a) | 56,500 | 266,680 | |
Imago BioSciences, Inc. (a) | 7,300 | 106,069 | |
Immunocore Holdings PLC ADR (a) | 72,970 | 3,853,546 | |
Inhibrx, Inc. (a)(b) | 71,500 | 1,268,410 | |
Instil Bio, Inc. (a) | 59,700 | 310,440 | |
Intarcia Therapeutics, Inc. warrants 12/6/24 (a)(d) | 7,022 | 0 | |
Intellia Therapeutics, Inc. (a) | 76,500 | 4,594,590 | |
Ionis Pharmaceuticals, Inc. (a) | 2,070,504 | 88,037,830 | |
Janux Therapeutics, Inc. (a) | 94,100 | 1,018,162 | |
Karuna Therapeutics, Inc. (a) | 372,499 | 95,009,595 | |
Kinnate Biopharma, Inc. (a) | 34,300 | 496,664 | |
Legend Biotech Corp. ADR (a) | 338,900 | 15,755,461 | |
Lexicon Pharmaceuticals, Inc. (a) | 146,922 | 404,036 | |
Lyell Immunopharma, Inc. (a)(b) | 431,000 | 2,887,700 | |
Moderna, Inc. (a) | 168,841 | 22,332,599 | |
Monte Rosa Therapeutics, Inc. (a) | 394,400 | 3,123,648 | |
Morphic Holding, Inc. (a) | 321,214 | 8,839,809 | |
Nuvalent, Inc. Class A (a) | 302,076 | 5,099,043 | |
Omega Therapeutics, Inc. (a) | 326,224 | 1,458,221 | |
ORIC Pharmaceuticals, Inc. (a) | 133,608 | 462,284 | |
Poseida Therapeutics, Inc. (a) | 745,959 | 2,469,124 | |
Protagonist Therapeutics, Inc. (a) | 136,995 | 1,194,596 | |
Prothena Corp. PLC (a) | 178,705 | 4,926,897 | |
PTC Therapeutics, Inc. (a) | 227,637 | 11,368,192 | |
Recursion Pharmaceuticals, Inc. (a)(b) | 474,100 | 4,982,791 | |
Regeneron Pharmaceuticals, Inc. (a) | 85,621 | 49,750,938 | |
Relay Therapeutics, Inc. (a) | 99,900 | 2,294,703 | |
Rigel Pharmaceuticals, Inc. (a) | 2,433,599 | 3,455,711 | |
Rubius Therapeutics, Inc. (a)(b) | 1,107,317 | 775,122 | |
Sage Therapeutics, Inc. (a) | 625,013 | 23,537,990 | |
Saluda Medical Pty Ltd. warrants (a)(c)(d) | 32,997 | 94,701 | |
Sana Biotechnology, Inc. (a)(b) | 171,700 | 1,169,277 | |
Scholar Rock Holding Corp. (a) | 507,934 | 4,236,170 | |
Scholar Rock Holding Corp. warrants 12/31/25 (a)(c) | 44,550 | 159,730 | |
Seagen, Inc. (a) | 5,800 | 894,882 | |
Seres Therapeutics, Inc. (a) | 1,438,326 | 7,392,996 | |
Shattuck Labs, Inc. (a) | 321,000 | 1,043,250 | |
Sigilon Therapeutics, Inc. (a) | 57,800 | 35,928 | |
Silverback Therapeutics, Inc. (a) | 221,184 | 1,203,241 | |
Springworks Therapeutics, Inc. (a)(b) | 704,800 | 19,572,296 | |
Synlogic, Inc. (a) | 576,900 | 576,900 | |
Syros Pharmaceuticals, Inc. (a) | 78,738 | 63,038 | |
Syros Pharmaceuticals, Inc. (a)(f) | 301,001 | 240,981 | |
Syros Pharmaceuticals, Inc. warrants 10/10/22 (a) | 35,253 | 0 | |
Tango Therapeutics, Inc. (a) | 233,856 | 958,810 | |
Taysha Gene Therapies, Inc. (a) | 145,908 | 461,069 | |
Tenaya Therapeutics, Inc. (a) | 10,500 | 46,095 | |
TG Therapeutics, Inc. (a) | 485,100 | 3,458,763 | |
Twist Bioscience Corp. (a) | 300,300 | 12,048,036 | |
Tyra Biosciences, Inc. | 27,900 | 184,419 | |
uniQure B.V. (a) | 51,449 | 1,005,313 | |
UNITY Biotechnology, Inc. (a) | 932,000 | 433,194 | |
UNITY Biotechnology, Inc. warrants 8/22/27 (a) | 700,000 | 96,699 | |
Vaxcyte, Inc. (a) | 226,080 | 5,914,253 | |
Vera Therapeutics, Inc. (a) | 129,982 | 2,824,509 | |
Vertex Pharmaceuticals, Inc. (a) | 58,793 | 16,565,516 | |
Verve Therapeutics, Inc. (a) | 115,800 | 4,442,088 | |
Vor Biopharma, Inc. (a) | 75,211 | 385,832 | |
Yumanity Therapeutics, Inc. (a) | 82,392 | 140,890 | |
Zai Lab Ltd. ADR (a) | 177,186 | 8,187,765 | |
Zentalis Pharmaceuticals, Inc. (a) | 192,144 | 5,151,381 | |
918,999,661 | |||
Health Care Equipment & Supplies - 3.1% | |||
Abbott Laboratories | 10,001 | 1,026,603 | |
DexCom, Inc. (a) | 352,384 | 28,969,489 | |
Figs, Inc. Class A (a) | 94,900 | 1,097,044 | |
Insulet Corp. (a) | 430,543 | 109,990,820 | |
Intuitive Surgical, Inc. (a) | 213,123 | 43,847,926 | |
Novocure Ltd. (a)(b) | 1,300,244 | 106,789,040 | |
Oddity Tech Ltd. (c)(d) | 2,226 | 776,941 | |
Outset Medical, Inc. (a) | 391,953 | 7,168,820 | |
Presbia PLC (a)(d) | 454,926 | 6,824 | |
PROCEPT BioRobotics Corp. | 330,162 | 13,364,958 | |
Shockwave Medical, Inc. (a) | 169,367 | 50,278,288 | |
363,316,753 | |||
Health Care Providers & Services - 1.4% | |||
Alignment Healthcare, Inc. (a) | 461,922 | 7,025,834 | |
AmerisourceBergen Corp. | 43,100 | 6,316,736 | |
Centene Corp. (a) | 242,090 | 21,725,157 | |
Guardant Health, Inc. (a) | 75,234 | 3,766,214 | |
Humana, Inc. | 61,143 | 29,457,475 | |
McKesson Corp. | 34,000 | 12,478,000 | |
Progyny, Inc. (a) | 34,700 | 1,395,287 | |
The Oncology Institute, Inc. (a)(c) | 377,375 | 2,396,331 | |
UnitedHealth Group, Inc. | 169,754 | 88,158,345 | |
172,719,379 | |||
Health Care Technology - 0.0% | |||
DNA Script (c)(d) | 85 | 62,278 | |
DNA Script (c)(d) | 324 | 237,388 | |
299,666 | |||
Life Sciences Tools & Services - 0.7% | |||
10X Genomics, Inc. Class B (a)(f) | 640,857 | 21,141,872 | |
Absci Corp. (a)(b) | 958,783 | 3,231,099 | |
Akoya Biosciences, Inc. (a) | 800 | 9,120 | |
Danaher Corp. | 12,433 | 3,355,791 | |
ICON PLC (a) | 7,400 | 1,552,742 | |
Olink Holding AB ADR (a) | 318,035 | 4,815,050 | |
Seer, Inc. (a) | 346,717 | 3,501,842 | |
Thermo Fisher Scientific, Inc. | 42,174 | 22,998,326 | |
WuXi AppTec Co. Ltd. (H Shares) (f) | 283,140 | 3,196,369 | |
Wuxi Biologics (Cayman), Inc. (a)(f) | 2,198,810 | 19,398,127 | |
83,200,338 | |||
Pharmaceuticals - 1.5% | |||
Arvinas Holding Co. LLC (a) | 53,000 | 2,244,020 | |
Atea Pharmaceuticals, Inc. (a) | 1,477,936 | 11,084,520 | |
Bristol-Myers Squibb Co. | 128,265 | 8,646,344 | |
Dragonfly Therapeutics, Inc. (a)(c)(d) | 126,113 | 1,799,633 | |
Eli Lilly & Co. | 153,800 | 46,329,174 | |
Fulcrum Therapeutics, Inc. (a) | 284,952 | 2,108,645 | |
GH Research PLC (a) | 301,400 | 4,686,770 | |
Hansoh Pharmaceutical Group Co. Ltd. (f) | 312,400 | 623,281 | |
Harmony Biosciences Holdings, Inc. (a) | 557,123 | 24,463,271 | |
Intra-Cellular Therapies, Inc. (a) | 950,809 | 47,787,660 | |
Nuvation Bio, Inc. (a) | 932,837 | 2,611,944 | |
OptiNose, Inc. (a) | 1,330,328 | 4,855,697 | |
Pfizer, Inc. | 79,200 | 3,582,216 | |
Pharvaris BV (a) | 41,400 | 376,326 | |
Pliant Therapeutics, Inc. (a) | 421,400 | 8,124,592 | |
Sienna Biopharmaceuticals, Inc. (a)(d) | 589,618 | 6 | |
Skyhawk Therapeutics, Inc. (a)(c)(d) | 126,063 | 1,471,155 | |
Theravance Biopharma, Inc. (a) | 290,245 | 2,615,107 | |
Theseus Pharmaceuticals, Inc. | 2,800 | 19,096 | |
UCB SA | 27,100 | 1,909,114 | |
175,338,571 | |||
TOTAL HEALTH CARE | 1,713,874,368 | ||
INDUSTRIALS - 5.9% | |||
Aerospace & Defense - 1.3% | |||
AeroVironment, Inc. (a) | 31,100 | 2,757,015 | |
Lockheed Martin Corp. | 57,300 | 24,072,303 | |
Raytheon Technologies Corp. | 174,000 | 15,616,500 | |
Space Exploration Technologies Corp. Class A (a)(c)(d) | 1,375,690 | 96,298,300 | |
The Boeing Co. (a) | 84,136 | 13,482,794 | |
152,226,912 | |||
Air Freight & Logistics - 0.2% | |||
Delhivery Private Ltd. (c) | 646,600 | 4,395,894 | |
United Parcel Service, Inc. Class B | 90,084 | 17,522,239 | |
21,918,133 | |||
Airlines - 1.2% | |||
Delta Air Lines, Inc. (a) | 989,190 | 30,734,133 | |
JetBlue Airways Corp. (a) | 98,414 | 766,645 | |
Ryanair Holdings PLC sponsored ADR (a) | 11,678 | 849,107 | |
Southwest Airlines Co. (a) | 1,302,537 | 47,803,108 | |
Spirit Airlines, Inc. (a) | 655,933 | 14,876,560 | |
United Airlines Holdings, Inc. (a) | 575,225 | 20,138,627 | |
Wheels Up Experience, Inc.: | |||
Class A (a) | 1,900,977 | 3,554,827 | |
rights (a)(d) | 23,018 | 17,264 | |
rights (a)(d) | 23,018 | 13,581 | |
rights (a)(d) | 23,018 | 11,049 | |
Wizz Air Holdings PLC (a)(f) | 731,783 | 18,175,401 | |
136,940,302 | |||
Construction & Engineering - 0.2% | |||
Fluor Corp. (a) | 349,200 | 9,232,848 | |
MasTec, Inc. (a)(b) | 48,300 | 3,888,150 | |
Quanta Services, Inc. | 51,500 | 7,276,950 | |
20,397,948 | |||
Electrical Equipment - 0.4% | |||
Eaton Corp. PLC | 66,524 | 9,089,839 | |
Emerson Electric Co. | 196,049 | 16,025,045 | |
Generac Holdings, Inc. (a) | 84,000 | 18,514,440 | |
NuScale Power Corp. (a)(b) | 49,200 | 675,024 | |
Rockwell Automation, Inc. | 35,800 | 8,482,452 | |
52,786,800 | |||
Industrial Conglomerates - 0.1% | |||
3M Co. | 22,380 | 2,782,953 | |
Honeywell International, Inc. | 41,783 | 7,911,611 | |
10,694,564 | |||
Machinery - 0.8% | |||
Caterpillar, Inc. | 114,760 | 21,197,320 | |
Deere & Co. | 98,852 | 36,105,693 | |
Fortive Corp. | 20,200 | 1,279,266 | |
Illinois Tool Works, Inc. | 72,153 | 14,057,569 | |
Ingersoll Rand, Inc. | 84,644 | 4,009,586 | |
Xylem, Inc. | 222,017 | 20,225,749 | |
96,875,183 | |||
Professional Services - 0.0% | |||
LegalZoom.com, Inc. (a)(b) | 230,800 | 2,377,240 | |
Sterling Check Corp. (b) | 25,700 | 546,896 | |
2,924,136 | |||
Road & Rail - 1.7% | |||
Avis Budget Group, Inc. (a) | 560,319 | 93,786,194 | |
Bird Global, Inc. (a)(c) | 228,339 | 97,021 | |
Bird Global, Inc.: | |||
Class A (a) | 542,383 | 230,459 | |
rights (a)(d) | 28,568 | 1,428 | |
rights (a)(d) | 28,568 | 857 | |
rights (a)(d) | 28,567 | 286 | |
Canadian Pacific Railway Ltd. (b) | 119,977 | 8,981,478 | |
CSX Corp. | 467,300 | 14,790,045 | |
Hertz Global Holdings, Inc. | 1,157,000 | 21,358,220 | |
Union Pacific Corp. | 296,561 | 66,580,910 | |
205,826,898 | |||
TOTAL INDUSTRIALS | 700,590,876 | ||
INFORMATION TECHNOLOGY - 34.8% | |||
Communications Equipment - 0.6% | |||
Arista Networks, Inc. (a) | 121,032 | 14,509,316 | |
Ciena Corp. (a) | 826,197 | 41,921,236 | |
Infinera Corp. (a)(b) | 3,001,675 | 16,449,179 | |
72,879,731 | |||
Electronic Equipment & Components - 0.2% | |||
Arlo Technologies, Inc. (a) | 99,811 | 607,849 | |
II-VI, Inc. (a) | 161,290 | 7,617,727 | |
TE Connectivity Ltd. | 1,941 | 244,974 | |
Trimble, Inc. (a) | 171,200 | 10,828,400 | |
19,298,950 | |||
IT Services - 3.8% | |||
Accenture PLC Class A | 112,500 | 32,451,750 | |
Actua Corp. (a)(d) | 562,258 | 5,623 | |
Block, Inc. Class A (a) | 80,285 | 5,532,439 | |
Cloudflare, Inc. (a)(b) | 1,266,781 | 79,262,487 | |
IBM Corp. | 136,795 | 17,571,318 | |
MasterCard, Inc. Class A | 358,349 | 116,237,665 | |
MongoDB, Inc. Class A (a) | 9,041 | 2,918,977 | |
Okta, Inc. (a) | 116,581 | 10,655,503 | |
PayPal Holdings, Inc. (a) | 167,027 | 15,607,003 | |
Shopify, Inc. Class A (a) | 459,790 | 14,556,720 | |
Snowflake, Inc. (a) | 98,025 | 17,737,624 | |
Toast, Inc. | 441,400 | 8,355,702 | |
Twilio, Inc. Class A (a) | 800 | 55,664 | |
Visa, Inc. Class A | 685,712 | 136,257,832 | |
457,206,307 | |||
Semiconductors & Semiconductor Equipment - 9.1% | |||
Advanced Micro Devices, Inc. (a) | 728,936 | 61,864,798 | |
Applied Materials, Inc. | 434,685 | 40,890,818 | |
ASML Holding NV | 14,485 | 7,096,781 | |
Broadcom, Inc. | 41,725 | 20,825,365 | |
Cirrus Logic, Inc. (a) | 347,266 | 26,631,830 | |
Enphase Energy, Inc. (a) | 70,300 | 20,136,732 | |
First Solar, Inc. (a) | 242,000 | 30,867,100 | |
GlobalFoundries, Inc. | 109,100 | 6,526,362 | |
KLA Corp. | 55,486 | 19,094,397 | |
Lam Research Corp. | 18,200 | 7,969,962 | |
Marvell Technology, Inc. | 765,041 | 35,819,220 | |
Micron Technology, Inc. | 85,531 | 4,835,067 | |
Monolithic Power Systems, Inc. | 20,900 | 9,471,462 | |
NVIDIA Corp. | 4,273,340 | 645,017,940 | |
onsemi (a) | 111,500 | 7,667,855 | |
Qualcomm, Inc. | 159,709 | 21,124,709 | |
Silicon Laboratories, Inc. (a) | 401,739 | 50,349,949 | |
SiTime Corp. (a) | 139,185 | 14,810,676 | |
SolarEdge Technologies, Inc. (a) | 7,700 | 2,124,969 | |
Taiwan Semiconductor Manufacturing Co. Ltd. sponsored ADR | 118,768 | 9,899,313 | |
Teradyne, Inc. | 81,850 | 6,927,784 | |
Texas Instruments, Inc. | 137,194 | 22,665,821 | |
Wolfspeed, Inc. (a)(b) | 101,729 | 11,543,190 | |
1,084,162,100 | |||
Software - 10.5% | |||
Adobe, Inc. (a) | 181,712 | 67,858,529 | |
Atlassian Corp. PLC (a) | 9,726 | 2,408,741 | |
Autodesk, Inc. (a) | 129,442 | 26,113,629 | |
Avalara, Inc. (a) | 34,504 | 3,160,221 | |
Bill.Com Holdings, Inc. (a) | 11,100 | 1,796,868 | |
Black Knight, Inc. (a) | 68,470 | 4,529,975 | |
C3.Ai, Inc. (a)(b) | 210,700 | 3,792,600 | |
Clear Secure, Inc. (a) | 1,400 | 32,116 | |
Coupa Software, Inc. (a) | 11,004 | 642,634 | |
Crowdstrike Holdings, Inc. (a) | 103,133 | 18,833,117 | |
Datadog, Inc. Class A (a) | 55,430 | 5,817,379 | |
Elastic NV (a) | 49,394 | 4,144,651 | |
Epic Games, Inc. (a)(c)(d) | 11,800 | 10,974,000 | |
ForgeRock, Inc. (b) | 29,500 | 503,270 | |
HubSpot, Inc. (a) | 37,417 | 12,611,026 | |
Informatica, Inc. (b) | 53,713 | 1,185,446 | |
Intuit, Inc. | 64,894 | 28,019,931 | |
Microsoft Corp. | 2,313,036 | 604,789,523 | |
Nutanix, Inc. Class A (a) | 3,393,257 | 58,703,346 | |
Oracle Corp. | 926,704 | 68,715,102 | |
Paycom Software, Inc. (a) | 10,200 | 3,582,240 | |
Paylocity Holding Corp. (a) | 23,297 | 5,614,577 | |
RingCentral, Inc. (a) | 44,342 | 1,908,480 | |
Riskified Ltd. Class B (a) | 417,774 | 2,113,936 | |
Salesforce.com, Inc. (a) | 1,444,749 | 225,554,214 | |
Samsara, Inc. (b) | 52,700 | 783,649 | |
SentinelOne, Inc. (a) | 49,000 | 1,338,190 | |
ServiceNow, Inc. (a) | 54,800 | 23,817,176 | |
Stripe, Inc. Class B (a)(c)(d) | 43,500 | 1,229,310 | |
The Trade Desk, Inc. (a) | 12,300 | 771,210 | |
UiPath, Inc. Class A (a)(b) | 1,184,348 | 19,482,525 | |
Workday, Inc. Class A (a) | 25,332 | 4,168,634 | |
Zoom Video Communications, Inc. Class A (a) | 160,953 | 12,940,621 | |
Zscaler, Inc. (a) | 92,765 | 14,771,899 | |
1,242,708,765 | |||
Technology Hardware, Storage & Peripherals - 10.6% | |||
Apple, Inc. | 7,390,328 | 1,161,907,354 | |
Pure Storage, Inc. Class A (a) | 3,351,786 | 97,101,240 | |
Samsung Electronics Co. Ltd. | 132,603 | 5,851,208 | |
1,264,859,802 | |||
TOTAL INFORMATION TECHNOLOGY | 4,141,115,655 | ||
MATERIALS - 1.7% | |||
Chemicals - 1.1% | |||
Albemarle Corp. | 50,000 | 13,398,000 | |
CF Industries Holdings, Inc. | 380,200 | 39,335,492 | |
Corteva, Inc. | 678,300 | 41,667,969 | |
DuPont de Nemours, Inc. | 246,846 | 13,734,511 | |
The Mosaic Co. | 315,400 | 16,990,598 | |
125,126,570 | |||
Containers & Packaging - 0.0% | |||
Sealed Air Corp. | 74,600 | 4,014,226 | |
Metals & Mining - 0.6% | |||
Barrick Gold Corp. (Canada) | 374,300 | 5,557,429 | |
Freeport-McMoRan, Inc. | 1,917,200 | 56,749,120 | |
Rio Tinto PLC sponsored ADR (b) | 252,800 | 14,230,112 | |
76,536,661 | |||
TOTAL MATERIALS | 205,677,457 | ||
REAL ESTATE - 0.4% | |||
Equity Real Estate Investment Trusts (REITs) - 0.3% | |||
American Tower Corp. | 87,598 | 22,254,272 | |
Equinix, Inc. | 4,600 | 3,023,902 | |
Simon Property Group, Inc. | 80,800 | 8,239,984 | |
33,518,158 | |||
Real Estate Management & Development - 0.1% | |||
CBRE Group, Inc. (a) | 142,700 | 11,267,592 | |
WeWork, Inc. (a) | 2,038,538 | 8,358,006 | |
19,625,598 | |||
TOTAL REAL ESTATE | 53,143,756 | ||
UTILITIES - 0.1% | |||
Electric Utilities - 0.1% | |||
ORSTED A/S (f) | 102,100 | 9,965,218 | |
TOTAL COMMON STOCKS (Cost $6,317,679,477) | 11,543,901,257 | ||
Preferred Stocks - 1.9% | |||
Shares | Value ($) | ||
Convertible Preferred Stocks - 1.8% | |||
COMMUNICATION SERVICES - 0.0% | |||
Interactive Media & Services - 0.0% | |||
Reddit, Inc.: | |||
Series B(a)(c)(d) | 37,935 | 1,492,363 | |
Series E(a)(c)(d) | 5,127 | 201,696 | |
Series F(c)(d) | 40,428 | 1,590,438 | |
3,284,497 | |||
CONSUMER DISCRETIONARY - 0.2% | |||
Automobiles - 0.0% | |||
Rad Power Bikes, Inc.: | |||
Series A(a)(c)(d) | 32,487 | 201,095 | |
Series C(a)(c)(d) | 127,831 | 791,274 | |
Series D(c)(d) | 215,900 | 1,336,421 | |
2,328,790 | |||
Hotels, Restaurants & Leisure - 0.1% | |||
Discord, Inc. Series I (c)(d) | 1,400 | 562,352 | |
MOD Super Fast Pizza Holdings LLC Series 3 (a)(c)(d)(e) | 23,686 | 6,201,042 | |
6,763,394 | |||
Internet & Direct Marketing Retail - 0.1% | |||
GoBrands, Inc.: | |||
Series G(a)(c)(d) | 26,833 | 6,478,023 | |
Series H(a)(c)(d) | 21,372 | 5,159,628 | |
Instacart, Inc.: | |||
Series H(a)(c)(d) | 13,904 | 668,921 | |
Series I(a)(c)(d) | 6,341 | 305,066 | |
12,611,638 | |||
Textiles, Apparel & Luxury Goods - 0.0% | |||
Freenome, Inc.: | |||
Series C(a)(c)(d) | 190,858 | 1,748,259 | |
Series D(c)(d) | 91,538 | 838,488 | |
Laronde, Inc. Series B (c)(d) | 66,432 | 1,344,584 | |
3,931,331 | |||
TOTAL CONSUMER DISCRETIONARY | 25,635,153 | ||
CONSUMER STAPLES - 0.1% | |||
Food & Staples Retailing - 0.1% | |||
Blink Health LLC Series C (a)(c)(d) | 197,068 | 7,476,760 | |
Food Products - 0.0% | |||
AgBiome LLC: | |||
Series C(a)(c)(d) | 338,565 | 2,220,986 | |
Series D(c)(d) | 126,371 | 818,884 | |
Bowery Farming, Inc. Series C1 (a)(c)(d) | 27,136 | 830,090 | |
3,869,960 | |||
Tobacco - 0.0% | |||
JUUL Labs, Inc. Series E (a)(c)(d) | 6,648 | 51,190 | |
TOTAL CONSUMER STAPLES | 11,397,910 | ||
FINANCIALS - 0.0% | |||
Diversified Financial Services - 0.0% | |||
Paragon Biosciences Emalex Capital, Inc.: | |||
Series B(a)(c)(d) | 198,234 | 1,112,093 | |
Series C(a)(c)(d) | 115,792 | 649,593 | |
1,761,686 | |||
HEALTH CARE - 0.5% | |||
Biotechnology - 0.4% | |||
Altos Labs, Inc. Series B (c)(d) | 122,084 | 2,337,713 | |
Ankyra Therapeutics Series B (c)(d) | 257,347 | 1,016,521 | |
Asimov, Inc. Series B (c)(d) | 15,783 | 1,085,713 | |
Bright Peak Therapeutics AG Series B (a)(c)(d) | 239,403 | 663,146 | |
Caris Life Sciences, Inc. Series D (a)(c)(d) | 255,590 | 1,415,969 | |
Castle Creek Biosciences, Inc.: | |||
Series D1(c)(d) | 4,460 | 908,680 | |
Series D2(c)(d) | 1,412 | 287,681 | |
Cleerly, Inc. Series C (c)(d) | 272,438 | 3,209,483 | |
Deep Genomics, Inc. Series C (a)(c)(d) | 129,534 | 1,299,226 | |
Dianthus Therapeutics, Inc. Series A (c)(d) | 287,993 | 1,075,049 | |
Element Biosciences, Inc.: | |||
Series B(a)(c)(d) | 250,956 | 3,428,059 | |
Series C(a)(c)(d) | 101,911 | 1,392,104 | |
ElevateBio LLC Series C (a)(c)(d) | 332,500 | 1,520,523 | |
Generate Biomedicines Series B (c)(d) | 157,390 | 1,279,581 | |
Inscripta, Inc.: | |||
Series D(a)(c)(d) | 308,833 | 1,877,705 | |
Series E(a)(c)(d) | 222,357 | 1,351,931 | |
Intarcia Therapeutics, Inc. Series EE (a)(c)(d) | 116,544 | 1 | |
Korro Bio, Inc.: | |||
Series B1(c)(d) | 241,420 | 461,112 | |
Series B2(c)(d) | 226,657 | 432,915 | |
LifeMine Therapeutics, Inc. Series C (c)(d) | 1,780,790 | 3,045,151 | |
National Resilience, Inc.: | |||
Series B(a)(c)(d) | 251,448 | 15,270,437 | |
Series C(a)(c)(d) | 44,850 | 2,723,741 | |
Quell Therapeutics Ltd. Series B (c)(d) | 760,965 | 928,377 | |
SalioGen Therapeutics, Inc. Series B (c)(d) | 8,766 | 653,681 | |
Saluda Medical Pty Ltd. Series D (c)(d) | 109,988 | 1,105,197 | |
Sonoma Biotherapeutics, Inc.: | |||
Series B(a)(c)(d) | 481,325 | 808,626 | |
Series B1(a)(c)(d) | 256,702 | 431,259 | |
T-Knife Therapeutics, Inc. Series B (a)(c)(d) | 199,356 | 763,533 | |
Treeline Biosciences Series A (a)(c)(d) | 250,200 | 1,428,642 | |
52,201,756 | |||
Health Care Equipment & Supplies - 0.0% | |||
Kardium, Inc. Series D6 (a)(c)(d) | 1,136,853 | 846,137 | |
Health Care Providers & Services - 0.0% | |||
Boundless Bio, Inc. Series B (a)(c)(d) | 616,102 | 560,653 | |
Conformal Medical, Inc. Series C (a)(c)(d) | 240,750 | 792,068 | |
Scorpion Therapeutics, Inc. Series B (a)(c)(d) | 242,077 | 302,596 | |
1,655,317 | |||
Health Care Technology - 0.1% | |||
Aledade, Inc.: | |||
Series B1(a)(c)(d) | 22,992 | 1,145,232 | |
Series E1(c)(d) | 17,916 | 892,396 | |
DNA Script: | |||
Series B(c)(d) | 4 | 2,931 | |
Series C(c)(d) | 2,060 | 1,509,319 | |
Omada Health, Inc. Series E (c)(d) | 435,062 | 1,200,771 | |
PrognomIQ, Inc.: | |||
Series A5(a)(c)(d) | 83,544 | 217,214 | |
Series B(a)(c)(d) | 198,721 | 516,675 | |
Series C(c)(d) | 66,506 | 172,916 | |
Wugen, Inc. Series B (a)(c)(d) | 96,718 | 504,868 | |
6,162,322 | |||
Pharmaceuticals - 0.0% | |||
Castle Creek Pharmaceutical Holdings, Inc.: | |||
Series B(a)(c)(d) | 4,910 | 1,087,663 | |
Series C(a)(c)(d) | 2,570 | 569,306 | |
Galvanize Therapeutics Series B (c)(d) | 1,018,908 | 1,742,333 | |
Nohla Therapeutics, Inc. Series B (a)(c)(d) | 3,126,919 | 31 | |
3,399,333 | |||
TOTAL HEALTH CARE | 64,264,865 | ||
INDUSTRIALS - 0.4% | |||
Aerospace & Defense - 0.3% | |||
Space Exploration Technologies Corp. Series G (a)(c)(d) | 53,937 | 37,755,900 | |
Construction & Engineering - 0.1% | |||
Beta Technologies, Inc.: | |||
Series A(a)(c)(d) | 10,986 | 1,133,426 | |
Series B, 6.00%(c)(d) | 17,147 | 1,769,056 | |
2,902,482 | |||
TOTAL INDUSTRIALS | 40,658,382 | ||
INFORMATION TECHNOLOGY - 0.5% | |||
Communications Equipment - 0.1% | |||
Meesho Series F (c)(d) | 62,461 | 4,262,339 | |
Xsight Labs Ltd. Series D (a)(c)(d) | 167,386 | 1,252,047 | |
5,514,386 | |||
Electronic Equipment & Components - 0.0% | |||
Enevate Corp. Series E (a)(c)(d) | 814,561 | 903,091 | |
Menlo Micro, Inc. Series C (c)(d) | 959,784 | 1,010,173 | |
1,913,264 | |||
IT Services - 0.1% | |||
AppNexus, Inc. Series E (Escrow) (a)(c)(d) | 209,665 | 6,567 | |
ByteDance Ltd. Series E1 (a)(c)(d) | 84,766 | 12,470,774 | |
12,477,341 | |||
Semiconductors & Semiconductor Equipment - 0.1% | |||
Alif Semiconductor Series C (c)(d) | 43,548 | 883,961 | |
Astera Labs, Inc.: | |||
Series A(c)(d) | 85,993 | 874,506 | |
Series B(c)(d) | 14,642 | 148,902 | |
Series C(c)(d) | 371,500 | 3,777,969 | |
Series D(c)(d) | 291,891 | 2,968,386 | |
GaN Systems, Inc.: | |||
Series F1(c)(d) | 50,937 | 341,787 | |
Series F2(c)(d) | 26,897 | 180,479 | |
SiMa.ai: | |||
Series B(a)(c)(d) | 338,113 | 2,397,525 | |
Series B1(c)(d) | 22,648 | 160,595 | |
11,734,110 | |||
Software - 0.2% | |||
Bolt Technology OU Series E (c)(d) | 13,569 | 2,107,197 | |
Databricks, Inc.: | |||
Series G(a)(c)(d) | 53,226 | 2,915,188 | |
Series H(c)(d) | 56,454 | 3,091,986 | |
Dataminr, Inc. Series D (a)(c)(d) | 442,241 | 9,923,888 | |
Evozyne LLC Series A (a)(c)(d) | 101,400 | 1,580,826 | |
Jet.Com, Inc. Series B1 (Escrow) (a)(c)(d) | 2,105,094 | 21 | |
Nuvia, Inc. Series B (a)(c) | 239,670 | 195,863 | |
Skyryse, Inc. Series B (c)(d) | 117,170 | 2,831,999 | |
Stripe, Inc. Series H (a)(c)(d) | 19,200 | 542,592 | |
Tenstorrent, Inc. Series C1 (a)(c)(d) | 21,000 | 1,181,880 | |
24,371,440 | |||
TOTAL INFORMATION TECHNOLOGY | 56,010,541 | ||
MATERIALS - 0.1% | |||
Chemicals - 0.0% | |||
Farmers Business Network, Inc. Series G (c)(d) | 36,990 | 2,054,795 | |
Metals & Mining - 0.1% | |||
Diamond Foundry, Inc. Series C (a)(c)(d) | 355,446 | 11,278,302 | |
TOTAL MATERIALS | 13,333,097 | ||
UTILITIES - 0.0% | |||
Independent Power and Renewable Electricity Producers - 0.0% | |||
Redwood Materials Series C (a)(c)(d) | 16,253 | 533,911 | |
TOTAL CONVERTIBLE PREFERRED STOCKS | 216,880,042 | ||
Nonconvertible Preferred Stocks - 0.1% | |||
CONSUMER DISCRETIONARY - 0.1% | |||
Automobiles - 0.0% | |||
Neutron Holdings, Inc. Series 1D (a)(c)(d) | 5,678,726 | 156,165 | |
Waymo LLC Series A2 (a)(c)(d) | 10,731 | 645,362 | |
801,527 | |||
Internet & Direct Marketing Retail - 0.1% | |||
Circle Internet Financial Ltd. Series E (c) | 137,221 | 6,688,248 | |
TOTAL CONSUMER DISCRETIONARY | 7,489,775 | ||
HEALTH CARE - 0.0% | |||
Pharmaceuticals - 0.0% | |||
Castle Creek Pharmaceutical Holdings, Inc. Series A4 (a)(c)(d) | 13,511 | 2,923,916 | |
Faraday Pharmaceuticals, Inc. Series B (a)(c)(d) | 219,824 | 235,212 | |
3,159,128 | |||
TOTAL NONCONVERTIBLE PREFERRED STOCKS | 10,648,903 | ||
TOTAL PREFERRED STOCKS (Cost $192,759,186) | 227,528,945 | ||
Convertible Bonds - 0.1% | |||
Principal Amount (g) | Value ($) | ||
CONSUMER DISCRETIONARY - 0.0% | |||
Automobiles - 0.0% | |||
Neutron Holdings, Inc.: | |||
4% 10/27/25 (c)(d)(h) | 1,347,300 | 1,195,459 | |
4% 5/22/27 (c)(d) | 857,900 | 947,894 | |
4% 6/12/27 (c)(d) | 25,455 | 28,125 | |
2,171,478 | |||
CONSUMER STAPLES - 0.1% | |||
Food & Staples Retailing - 0.1% | |||
Blink Health LLC 5% 1/15/24 (c)(d) | 3,000,000 | 3,048,600 | |
FINANCIALS - 0.0% | |||
Diversified Financial Services - 0.0% | |||
Paragon Biosciences Emalex Capital, Inc. 1.26% (c)(d)(i) | 382,943 | 382,943 | |
TOTAL CONVERTIBLE BONDS (Cost $5,613,598) | 5,603,021 | ||
Preferred Securities - 0.0% | |||
Principal Amount (g) | Value ($) | ||
HEALTH CARE - 0.0% | |||
Biotechnology - 0.0% | |||
Intarcia Therapeutics, Inc. 6% 7/18/23 (c)(d)(j) | 614,446 | 0 | |
Health Care Equipment & Supplies - 0.0% | |||
Kardium, Inc. 0% (c)(d)(i) | 1,612,660 | 1,612,660 | |
TOTAL HEALTH CARE | 1,612,660 | ||
INFORMATION TECHNOLOGY - 0.0% | |||
Electronic Equipment & Components - 0.0% | |||
Enevate Corp. 0% 1/29/23 (c)(d) | 346,804 | 346,804 | |
Semiconductors & Semiconductor Equipment - 0.0% | |||
GaN Systems, Inc. 0% (c)(d)(i) | 1,193,899 | 1,193,899 | |
Software - 0.0% | |||
Tenstorrent, Inc. 0% (c)(d)(i) | 1,170,000 | 1,170,000 | |
TOTAL INFORMATION TECHNOLOGY | 2,710,703 | ||
TOTAL PREFERRED SECURITIES (Cost $4,937,809) | 4,323,363 | ||
Money Market Funds - 2.6% | |||
Shares | Value ($) | ||
Fidelity Cash Central Fund 2.33% (k) | 89,944,189 | 89,962,178 | |
Fidelity Securities Lending Cash Central Fund 2.34% (k)(l) | 219,392,657 | 219,414,596 | |
TOTAL MONEY MARKET FUNDS (Cost $309,376,774) | 309,376,774 | ||
TOTAL INVESTMENT IN SECURITIES - 101.7% (Cost $6,830,366,844) | 12,090,733,360 |
NET OTHER ASSETS (LIABILITIES) - (1.7)% (m) | (200,056,760) |
NET ASSETS - 100.0% | 11,890,676,600 |
Futures Contracts | |||||
Number of contracts | Expiration Date | Notional Amount ($) | Value ($) | Unrealized Appreciation/ (Depreciation) ($) | |
Purchased | |||||
Equity Index Contracts | |||||
CME E-mini S&P 500 Index Contracts (United States) | 261 | Sep 2022 | 51,632,325 | (1,715,600) | (1,715,600) |
The notional amount of futures purchased as a percentage of Net Assets is 0.4% |
Legend
(a) | Non-income producing |
(b) | Security or a portion of the security is on loan at period end. |
(c) | Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $425,947,021 or 3.6% of net assets. |
(d) | Level 3 security |
(e) | Investment is owned by a wholly-owned subsidiary (Subsidiary) that is treated as a corporation for U.S. tax purposes. |
(f) | Security exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At the end of the period, the value of these securities amounted to $74,058,125 or 0.6% of net assets. |
(g) | Amount is stated in United States dollars unless otherwise noted. |
(h) | Security initially issued at one coupon which converts to a higher coupon at a specified date. The rate shown is the rate at period end. |
(i) | Security is perpetual in nature with no stated maturity date. |
(j) | Non-income producing - Security is in default. |
(k) | Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request. |
(l) | Investment made with cash collateral received from securities on loan. |
(m) | Includes $1,830,000 of cash collateral to cover margin requirements for futures contracts. |
Additional information on each restricted holding is as follows: | ||
Security | Acquisition Date | Acquisition Cost ($) |
Adimab LLC | 9/17/14 - 6/05/15 | 11,639,813 |
AgBiome LLC Series C | 6/29/18 | 2,144,369 |
AgBiome LLC Series D | 9/03/21 | 749,101 |
Aledade, Inc. Series B1 | 5/07/21 | 880,380 |
Aledade, Inc. Series E1 | 5/20/22 | 892,475 |
Alif Semiconductor Series C | 3/08/22 | 883,961 |
Altos Labs, Inc. Series B | 7/22/22 | 2,337,713 |
Ankyra Therapeutics Series B | 8/26/21 | 1,449,327 |
Ant International Co. Ltd. Class C | 5/16/18 | 2,351,948 |
AppNexus, Inc. Series E (Escrow) | 8/01/14 | 0 |
Asimov, Inc. Series B | 10/29/21 | 1,462,779 |
Astera Labs, Inc. Series A | 5/17/22 | 874,506 |
Astera Labs, Inc. Series B | 5/17/22 | 148,902 |
Astera Labs, Inc. Series C | 8/24/21 | 1,248,909 |
Astera Labs, Inc. Series D | 5/17/22 | 2,968,386 |
Beta Technologies, Inc. Series A | 4/09/21 | 804,944 |
Beta Technologies, Inc. Series B, 6.00% | 4/04/22 | 1,769,056 |
Bird Global, Inc. | 5/11/21 | 2,283,390 |
Blink Health LLC Series A1 | 12/30/20 | 232,676 |
Blink Health LLC Series C | 11/07/19 - 7/14/21 | 7,523,268 |
Blink Health LLC 5% 1/15/24 | 7/15/22 | 3,000,000 |
Bolt Technology OU Series E | 1/03/22 | 3,525,179 |
Boundless Bio, Inc. Series B | 4/23/21 | 831,738 |
Bowery Farming, Inc. Series C1 | 5/18/21 | 1,634,925 |
Bright Peak Therapeutics AG Series B | 5/14/21 | 935,108 |
ByteDance Ltd. Series E1 | 11/18/20 | 9,288,165 |
Caris Life Sciences, Inc. Series D | 5/11/21 | 2,070,279 |
Castle Creek Biosciences, Inc. Series D1 | 4/19/22 | 959,034 |
Castle Creek Biosciences, Inc. Series D2 | 6/28/21 | 242,100 |
Castle Creek Pharmaceutical Holdings, Inc. Series A4 | 9/29/16 | 4,471,547 |
Castle Creek Pharmaceutical Holdings, Inc. Series B | 10/09/18 | 2,022,184 |
Castle Creek Pharmaceutical Holdings, Inc. Series C | 12/09/19 | 1,058,455 |
Cibus Corp. Series C | 2/16/18 - 6/23/21 | 3,557,388 |
Circle Internet Financial Ltd. Series E | 5/11/21 | 2,227,100 |
Cleerly, Inc. Series C | 7/08/22 | 3,209,483 |
Conformal Medical, Inc. Series C | 7/24/20 | 882,846 |
Cyclerion Therapeutics, Inc. | 4/02/19 | 2,229,495 |
Databricks, Inc. Series G | 2/01/21 | 3,146,861 |
Databricks, Inc. Series H | 8/31/21 | 4,148,473 |
Dataminr, Inc. Series D | 2/18/15 - 3/06/15 | 5,638,573 |
Deep Genomics, Inc. Series C | 7/21/21 | 1,878,398 |
Delhivery Private Ltd. | 5/20/21 | 3,156,208 |
Diamond Foundry, Inc. Series C | 3/15/21 | 8,530,704 |
Dianthus Therapeutics, Inc. Series A | 4/06/22 | 1,251,762 |
Discord, Inc. Series I | 9/15/21 | 770,874 |
DNA Script | 12/17/21 | 327,504 |
DNA Script Series B | 12/17/21 | 3,203 |
DNA Script Series C | 10/01/21 | 1,791,891 |
Dragonfly Therapeutics, Inc. | 12/19/19 | 3,336,950 |
Element Biosciences, Inc. Series B | 12/13/19 | 1,315,160 |
Element Biosciences, Inc. Series C | 6/21/21 | 2,094,954 |
ElevateBio LLC Series C | 3/09/21 | 1,394,838 |
Enevate Corp. Series E | 1/29/21 | 903,092 |
Enevate Corp. 0% 1/29/23 | 1/29/21 | 346,804 |
Epic Games, Inc. | 7/13/20 - 7/30/20 | 6,785,000 |
Evozyne LLC Series A | 4/09/21 | 2,278,458 |
Fanatics, Inc. Class A | 8/13/20 - 12/15/21 | 3,989,927 |
Faraday Pharmaceuticals, Inc. Series B | 12/30/19 | 288,996 |
Farmers Business Network, Inc. Series G | 9/15/21 | 2,299,217 |
Freenome, Inc. Series C | 8/14/20 | 1,262,201 |
Freenome, Inc. Series D | 11/22/21 | 690,407 |
Galvanize Therapeutics Series B | 3/29/22 | 1,764,020 |
GaN Systems, Inc. Series F1 | 11/30/21 | 431,946 |
GaN Systems, Inc. Series F2 | 11/30/21 | 228,087 |
GaN Systems, Inc. 0% | 11/30/21 | 1,193,899 |
Generate Biomedicines Series B | 11/02/21 | 1,865,072 |
GoBrands, Inc. Series G | 3/02/21 | 6,700,664 |
GoBrands, Inc. Series H | 7/22/21 | 8,302,821 |
Inscripta, Inc. Series D | 11/13/20 | 1,411,367 |
Inscripta, Inc. Series E | 3/30/21 | 1,963,412 |
Instacart, Inc. Series H | 11/13/20 | 834,240 |
Instacart, Inc. Series I | 2/26/21 | 792,625 |
Intarcia Therapeutics, Inc. Series EE | 9/02/16 | 6,992,640 |
Intarcia Therapeutics, Inc. 6% 7/18/23 | 2/26/19 | 614,446 |
Jet.Com, Inc. Series B1 (Escrow) | 3/19/18 | 0 |
JUUL Labs, Inc. Class A | 7/06/18 | 392,042 |
JUUL Labs, Inc. Series E | 7/06/18 | 196,006 |
Kardium, Inc. Series D6 | 12/30/20 | 1,154,861 |
Kardium, Inc. 0% | 12/30/20 | 1,612,660 |
Korro Bio, Inc. Series B1 | 12/17/21 | 630,106 |
Korro Bio, Inc. Series B2 | 12/17/21 | 630,106 |
Laronde, Inc. Series B | 8/13/21 | 1,860,096 |
LifeMine Therapeutics, Inc. Series C | 2/15/22 | 3,626,739 |
Meesho Series F | 9/21/21 | 4,789,029 |
Menlo Micro, Inc. Series C | 2/09/22 | 1,272,194 |
MOD Super Fast Pizza Holdings LLC Series 3 | 11/03/16 - 5/15/19 | 3,421,899 |
National Resilience, Inc. Series B | 12/01/20 | 3,434,780 |
National Resilience, Inc. Series C | 6/28/21 | 1,991,789 |
Neutron Holdings, Inc. | 2/04/21 | 4,384 |
Neutron Holdings, Inc. Series 1D | 1/25/19 | 1,377,091 |
Neutron Holdings, Inc. 4% 10/27/25 | 10/29/21 | 1,347,300 |
Neutron Holdings, Inc. 4% 5/22/27 | 6/04/20 | 857,900 |
Neutron Holdings, Inc. 4% 6/12/27 | 6/12/20 | 25,455 |
Nohla Therapeutics, Inc. Series B | 5/01/18 | 1,096,231 |
Nuvia, Inc. Series B | 3/16/21 | 195,862 |
Oddity Tech Ltd. | 1/06/22 | 958,093 |
Omada Health, Inc. Series E | 12/22/21 | 2,608,284 |
Paragon Biosciences Emalex Capital, Inc. Series B | 9/18/19 | 2,020,004 |
Paragon Biosciences Emalex Capital, Inc. Series C | 2/26/21 | 1,238,974 |
Paragon Biosciences Emalex Capital, Inc. 1.26% | 5/18/22 | 382,943 |
PrognomIQ, Inc. Series A5 | 8/20/20 | 50,461 |
PrognomIQ, Inc. Series B | 9/11/20 | 454,100 |
PrognomIQ, Inc. Series C | 2/16/22 | 203,508 |
Quell Therapeutics Ltd. Series B | 11/24/21 | 1,438,224 |
Rad Power Bikes, Inc. | 1/21/21 | 1,202,019 |
Rad Power Bikes, Inc. Series A | 1/21/21 | 156,712 |
Rad Power Bikes, Inc. Series C | 1/21/21 | 616,636 |
Rad Power Bikes, Inc. Series D | 9/17/21 | 2,069,142 |
Reddit, Inc. Series B | 7/26/17 | 538,544 |
Reddit, Inc. Series E | 5/18/21 | 217,765 |
Reddit, Inc. Series F | 8/11/21 | 2,498,224 |
Redwood Materials Series C | 5/28/21 | 770,449 |
SalioGen Therapeutics, Inc. Series B | 12/10/21 | 928,004 |
Saluda Medical Pty Ltd. Series D | 1/20/22 | 1,402,995 |
Saluda Medical Pty Ltd. warrants | 1/20/22 | 0 |
Scholar Rock Holding Corp. warrants 12/31/25 | 6/17/22 | 0 |
Scorpion Therapeutics, Inc. Series B | 1/08/21 | 585,688 |
SiMa.ai Series B | 5/10/21 | 1,733,641 |
SiMa.ai Series B1 | 4/25/22 | 160,595 |
Skyhawk Therapeutics, Inc. | 5/21/21 | 2,069,954 |
Skyryse, Inc. Series B | 10/21/21 | 2,891,752 |
Sonoma Biotherapeutics, Inc. Series B | 7/26/21 | 951,243 |
Sonoma Biotherapeutics, Inc. Series B1 | 7/26/21 | 760,993 |
Space Exploration Technologies Corp. Class A | 10/16/15 - 4/06/17 | 12,876,729 |
Space Exploration Technologies Corp. Series G | 1/20/15 | 4,177,960 |
Stripe, Inc. Class B | 5/18/21 | 1,745,585 |
Stripe, Inc. Series H | 3/15/21 | 770,400 |
T-Knife Therapeutics, Inc. Series B | 6/30/21 | 1,150,045 |
Tenstorrent, Inc. Series C1 | 4/23/21 | 1,248,540 |
Tenstorrent, Inc. 0% | 4/23/21 | 1,170,000 |
The Beauty Health Co. | 12/08/20 | 5,538,280 |
The Oncology Institute, Inc. | 6/28/21 | 3,773,750 |
Tory Burch LLC | 5/14/15 | 17,500,910 |
Treeline Biosciences Series A | 7/30/21 | 1,958,441 |
Waymo LLC Series A2 | 5/08/20 | 921,441 |
Wugen, Inc. Series B | 7/09/21 | 750,038 |
Xsight Labs Ltd. Series D | 2/16/21 | 1,338,418 |
Affiliated Central Funds
Fiscal year to date information regarding the Fund's investments in Fidelity Central Funds, including the ownership percentage, is presented below.
Affiliate | Value, beginning of period ($) | Purchases ($) | Sales Proceeds ($) | Dividend Income ($) | Realized Gain (loss) ($) | Change in Unrealized appreciation (depreciation) ($) | Value, end of period ($) | %ownership, end of period |
Fidelity Cash Central Fund 2.33% | 76,613,355 | 4,431,172,868 | 4,417,824,045 | 803,097 | - | - | 89,962,178 | 0.2% |
Fidelity Securities Lending Cash Central Fund 2.34% | 317,559,429 | 941,105,622 | 1,039,250,455 | 1,053,585 | - | - | 219,414,596 | 0.6% |
Total | 394,172,784 | 5,372,278,490 | 5,457,074,500 | 1,856,682 | - | - | 309,376,774 | |
Amounts in the income column in the above table include any capital gain distributions from underlying funds.
Amount for Fidelity Securities Lending Cash Central Fund represents the income earned on investing cash collateral, less rebates paid to borrowers and any lending agent fees associated with the loan, plus any premium payments received for lending certain types of securities.
Investment Valuation
Investments are valued as of 4:00 p.m. Eastern time on the last calendar day of the period. Security transactions are accounted for as of trade date. The Board of Trustees (the Board) has delegated the day to day responsibility for the valuation of the Fund's investments to the Fair Value Committee (the Committee) established by the Fund's investment adviser. In accordance with valuation policies and procedures approved by the Board, the Fund attempts to obtain prices from one or more third party pricing vendors or brokers to value its investments. When current market prices, quotations or currency exchange rates are not readily available or reliable, investments will be fair valued in good faith by the Committee, in accordance with procedures adopted by the Board. Factors used in determining fair value vary by investment type and may include market or investment specific events, changes in interest rates and credit quality. The frequency with which these procedures are used cannot be predicted and they may be utilized to a significant extent. The Committee oversees the Fund's valuation policies and procedures and reports to the Board on the Committee's activities and fair value determinations. The Board monitors the appropriateness of the procedures used in valuing the Fund's investments and ratifies the fair value determinations of the Committee.
The inputs to valuation techniques used to value investments are categorized into a disclosure hierarchy consisting of three levels as shown below:
Level 1 - Unadjusted quoted prices in active markets for identical investments
Level 2 - other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, etc.)
Level 3 - unobservable inputs (including the Fund's own assumptions based on the best information available)
Valuation techniques used to value investments by major category are as follows:
Equity securities, including restricted securities, for which market quotations are readily available, are valued at the last reported sale price or official closing price as reported by a third party pricing vendor on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy. In the event there were no sales during the day or closing prices are not available, securities are valued at the last quoted bid price or may be valued using the last available price and are generally categorized as Level 2 in the hierarchy. For any foreign equity securities, when market or security specific events arise, comparisons to the valuation of American Depositary Receipts (ADRs), futures contracts, Exchange-Traded Funds (ETFs) and certain indexes as well as quoted prices for similar securities may be used and would be categorized as Level 2 in the hierarchy. For equity securities, including restricted securities, where observable inputs are limited, assumptions about market activity and risk are used and these securities may be categorized as Level 3 in the hierarchy.
Securities, including private placements or other restricted securities, for which observable inputs are not available are valued using alternate valuation approaches, including the market approach, the income approach and cost approach, and are categorized as Level 3 in the hierarchy. The market approach considers factors including the price of recent investments in the same or a similar security or financial metrics of comparable securities. The income approach considers factors including expected future cash flows, security specific risks and corresponding discount rates. The cost approach considers factors including the value of the security's underlying assets and liabilities.
Debt securities, including restricted securities, are valued based on evaluated prices received from third party pricing vendors or from brokers who make markets in such securities. Convertible Bonds and Preferred Securities are valued by pricing vendors who utilize matrix pricing which considers yield or price of bonds of comparable quality, coupon, maturity and type or by broker-supplied prices. When independent prices are unavailable or unreliable, debt securities may be valued utilizing pricing methodologies which consider similar factors that would be used by third party pricing vendors. Debt securities are generally categorized as Level 2 in the hierarchy but may be Level 3 depending on the circumstances.
Futures contracts are valued at the settlement price established each day by the board of trade or exchange on which they are traded and are categorized as Level 1 in the hierarchy.
Investments in any open-end mutual funds are valued at their closing net asset value (NAV) each business day and are categorized as Level 1 in the hierarchy.
Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy.
Derivative Instruments
Risk Exposures and the Use of Derivative Instruments: The Fund's investment objectives allow the Fund to enter into various types of derivative contracts. Derivatives are investments whose value is primarily derived from underlying assets, indices or reference rates and may be transacted on an exchange or over-the-counter (OTC). Derivatives may involve a future commitment to buy or sell a specified asset based on specified terms, to exchange future cash flows at periodic intervals based on a notional principal amount, or for one party to make one or more payments upon the occurrence of specified events in exchange for periodic payments from the other party.
The Fund used derivatives to increase returns, to gain exposure to certain types of assets and/or to manage exposure to certain risks as defined below. The success of any strategy involving derivatives depends on analysis of numerous economic factors, and if the strategies for investment do not work as intended, the Fund may not achieve its objectives.
The Fund's use of derivatives increased or decreased its exposure to the following risk(s):
Equity Risk - Equity risk relates to the fluctuations in the value of financial instruments as a result of changes in market prices (other than those arising from interest rate risk or foreign exchange risk), whether caused by factors specific to an individual investment, its issuer, or all factors affecting all instruments traded in a market or market segment.
Investing in derivatives may involve greater risks than investing in the underlying assets directly and, to varying degrees, may involve risk of loss in excess of any initial investment and collateral received. In addition, there may be the risk that the change in value of the derivative contract does not correspond to the change in value of the underlying instrument.
Futures Contracts: A futures contract is an agreement between two parties to buy or sell a specified underlying instrument for a specified price at a specified future date.
The Fund used futures contracts to manage its exposure to the stock market.
Open futures contracts at period end are presented in the Schedule of Investments under the caption "Futures Contracts". The underlying face amount at value reflects each contract's exposure to the underlying instrument or index at period end. Any securities and/or cash deposited to meet initial margin requirements are identified in the Schedule of Investments.
For additional information on the Fund's significant accounting policies, please refer to the Fund's most recent semiannual or annual shareholder report.
The fund's schedule of investments as of the date on the cover of this report has not been audited. This report is provided for the general information of the fund's shareholders. For more information regarding the fund and its holdings, please see the fund's most recent prospectus and annual report.
Third party trademarks and service marks are the property of their respective owners. All other trademarks and service marks are the property of FMR LLC or an affiliate.